Corlopam (fenoldopam mesylate) is an intravenous medication indicated for the short-term management of severe hypertension. It is primarily used when a rapid, but quickly reversible, reduction of elevated blood pressure is clinically required.

Quick Facts: Corlopam Therapeutic Uses

• Adults: Management of severe hypertension, including hypertensive emergencies with potential for deteriorating end-organ function.
• Pediatric Patients: Short-term use for the reduction of high blood pressure.

This therapy is administered in a hospital setting and is designed to help stabilize blood pressure levels quickly. It provides a means to manage dangerously high blood pressure until a patient can transition to appropriate oral treatment. Its use is clinically established for the critical care management of high blood pressure.

Population Eligibility for Corlopam (Fenoldopam Mesylate)

The official regulatory documentation for Corlopam strictly defines the populations allowed to use the medicine and those who are restricted or excluded.

Contraindications and Absolute Non-Eligibility

While the official prescribing information lists no formal contraindications, the drug contains sodium metabisulfite, which requires absolute exclusion for patients with a known sulfite sensitivity or allergy due to the risk of severe allergic reactions.

Age and Condition Restrictions

Population Group	Eligibility Status	Restriction/Limitation
Adult Patients	Permitted	Restricted to short-term (up to 48 hours), in-hospital use.
Pediatric Patients	Permitted	Restricted to short-term (up to 4 hours) use; data supports use in children 1 month and older.
Pregnant Patients	Conditional	Insufficient data exists; use is based on clinical necessity outweighing risks of severe maternal hypertension.
Lactating Patients	Not Recommended	Women should not breastfeed during treatment due to potential adverse effects on the infant.
Glaucoma Patients	Requires Caution	Use requires caution due to the risk of increasing intraocular pressure.
Hepatic/Renal Impairment	Permitted	Clearance is not altered in severe hepatic failure or end-stage renal disease; no adjustment or restriction is required.

Interactions with other medicines and products

Official regulatory documentation for Corlopam (fenoldopam mesylate) identifies specific pharmacodynamic restrictions and provides clarity regarding its pharmacokinetic profile. The primary restriction is the mandated avoidance of co-administration with beta-adrenergic blocking agents (beta-blockers). This restriction exists because beta-blockers may inhibit the body’s compensatory sympathetic reflex response to fenoldopam's potent vasodilation, which could result in clinically significant pronounced hypotension.

Pharmacokinetic Interaction Profile

The regulatory profile is further defined by the documented absence of known pharmacokinetic interactions related to common metabolic pathways. Official statements indicate that Cytochrome P-450 (CYP) enzymes do not participate in the drug's clearance pathway, meaning the risk of exposure-altering interactions with CYP inhibitors or inducers is officially absent. Furthermore, the clearance of fenoldopam is officially reported as not altered in adult patients with severe hepatic failure or those with end-stage renal disease, indicating no increased risk of accumulation in these populations. The official U.S. label lists no formal drug-drug contraindications; the only formal contraindication is for documented hypersensitivity to the product's components, such as sodium metabisulfite.

Activation of D1 Receptors and Smooth Muscle Relaxation

Fenoldopam operates as a selective agonist for the Dopamine D1 receptors found on the body's arterioles. This specific receptor engagement triggers the Gs-coupled signaling cascade, significantly increasing intracellular cAMP and subsequently inactivating Myosin Light Chain Kinase (MLCK). This molecular sequence forces the arterial smooth muscle to relax and widen (vasodilation), which is the primary mechanism resulting in a reduction of the pressure gradient across the systemic circulation.

Modulation of Systemic Resistance and Renal Flow

The widespread arteriolar relaxation produced by the mechanism drastically reduces Systemic Vascular Resistance (SVR). Furthermore, the drug’s selectivity is observed in the kidney's vascular beds, causing increased Renal Blood Flow (RBF). This action contributes to the preservation of renal perfusion and stimulates natriuresis (sodium excretion) via tubular D1 receptors.

The Physiological Baroreceptor Constraint

The drug’s mechanism is constrained by the natural baroreceptor reflex, a homeostatic feedback loop that senses the rapid fall in systemic pressure caused by vasodilation. In response, this reflex increases sympathetic output to the heart, which can trigger reflex tachycardia that acts physiologically to limit the extent of the blood pressure reduction.

How Corlopam is Used: Official Administration Guidelines

Corlopam (fenoldopam mesylate) is an injectable medication whose use is governed by standardized clinical protocols. This drug is intended for short-term management and must be administered exclusively within a supervised hospital setting via continuous infusion.

---

Administration and Preparation

Instruction Type	Requirement
Route of Administration	Continuous Intravenous (IV) Infusion only.
Preparation	The 10 mg/mL concentrate must be diluted before use.
Approved Diluents	0.9% Sodium Chloride Injection or 5% Dextrose in Water.
Final Concentration	Typically 40 mcg/mL for adults and 60 mcg/mL for pediatric patients.

---

Labeled Dosing and Scheduling

Corlopam dosing is weight-based and requires careful, gradual adjustment (titration) during administration. The rate of the continuous infusion is measured in micrograms per minute per kilogram (mcg/kg/min).

Population	Initial Dose	Titration Increment & Interval
Adults	0.01 to 0.3 mcg/kg/min	Increase by 0.05 to 0.1 mcg/kg/min every 15 minutes or longer.
Pediatrics	0.2 mcg/kg/min	Increase by 0.3 to 0.5 mcg/kg/min every 20 to 30 minutes.

---

Use Duration

Treatment duration is limited to the period required for acute blood pressure control. Adult infusions are typically maintained for up to 48 hours, while pediatric infusions are typically limited to 4 hours.

Corlopam (fenoldopam mesylate) is indicated for the in-hospital, short-term management of severe hypertension, including hypertensive emergencies. Evidence from clinical studies supports its use when a rapid, yet quickly reversible, reduction in blood pressure is needed.

Clinical Efficacy in Severe Hypertension

Clinical trials have investigated the effect of fenoldopam administration in adult patients experiencing hypertensive emergencies. In these studies, continuous intravenous infusion of fenoldopam has been associated with dose-related decreases in both systolic and diastolic blood pressure, often observed within minutes of starting the infusion. Studies comparing fenoldopam to another rapid-acting agent, nitroprusside, in severely hypertensive adults have shown comparable rates of blood pressure reduction to the target goals. The effect of fenoldopam on blood pressure has been shown to be rapid in onset and generally reversible, with blood pressure returning gradually toward pre-treatment levels following discontinuation of the infusion.

Evidence in Specific Populations

• Patients with Impaired Kidney Function: Fenoldopam has a pharmacological action that is thought to support blood flow to the kidneys, which may be a beneficial consideration in managing hypertensive patients who also have compromised kidney function. Clinical data suggest that fenoldopam clearance is not significantly altered in adult patients with severe hepatic failure or end-stage kidney disease.
• Pediatric Patients: Fenoldopam is indicated for the short-term reduction of blood pressure in pediatric patients in a hospital setting. Retrospective studies in children, including those with kidney disease and hypertensive crises, have suggested an association between fenoldopam infusion and a reduction in blood pressure after several hours of treatment.

Common questions about Corlopam (FAQ)

---

Q: How quickly does Corlopam usually start working?

The official product information indicates that the onset of action is rapid, with effects generally observed within minutes of starting the continuous intravenous infusion in a supervised hospital setting.

Q: Does Corlopam continue to work after the infusion is stopped?

Corlopam has a short duration of effect in the body. Official regulatory documents indicate that upon discontinuation of the infusion, blood pressure returns gradually toward pre-treatment levels.

Q: Does Corlopam interact with commonly used blood pressure medicines?

Regulatory labeling advises avoiding co-administration with beta-blockers, which are a class of common blood pressure medicines. This is because combining the two may lead to pronounced hypotension, or severely low blood pressure.

Q: Is it safe to take Corlopam if a patient is also on a diuretic?

The official label does not list a formal drug-drug interaction with diuretics (water pills). However, regulatory information notes that the drug can cause hypokalemia (low potassium in the blood). For this reason, serum potassium levels are typically monitored during treatment, according to the official product information.

Q: What are the official guidelines regarding Corlopam use during pregnancy?

Corlopam is officially classified as Pregnancy Category B. This means that while animal studies did not show evidence of harm to the fetus, there are no adequate and well-controlled studies in pregnant women. Official guidelines state the drug should only be used during pregnancy if it is clearly needed.

Q: Does Corlopam affect the brain or cause dizziness?

The official safety profile reports some side effects that may indicate effects on the central nervous system. Specifically, regulatory documents list Dizziness and Insomnia (trouble sleeping) as reported adverse reactions.

Q: What if a patient misses their usual blood pressure medication while receiving Corlopam?

Corlopam is a short-term, acute treatment provided in a hospital setting. Official regulatory information indicates that oral blood pressure agents can be initiated or added to the patient's existing regimen while the Corlopam infusion is ongoing or after it has been stopped.

Q: Can Corlopam affect blood sugar levels?

The regulatory safety profile includes reports of Hyperglycemia (high blood sugar) as an adverse reaction under the metabolism and nutrition disorders class. This is based on clinical trial data.

Q: What is the difference between Corlopam and other rapid blood pressure medications?

Official prescribing information describes Corlopam as unique due to its specific mechanism of action. It functions as a selective Dopamine D1-receptor agonist, a distinct pharmacological class that promotes the widening of the arteries (vasodilation) to rapidly lower blood pressure.

Q: Is Corlopam the same kind of medicine as nitroglycerin?

No. Official documents classify Corlopam as a D1-receptor agonist. This is a different pharmacological mechanism than that of organic nitrates, such as nitroglycerin, which rely on different pharmacological pathways to cause vasodilation.

Q: Are there any serious side effects associated with Corlopam that I should know about?

Official regulatory safety data highlights the potential for serious adverse reactions. These have included cardiogenic shock, myocardial infarction (heart attack), and cardiac arrest.

Q: What happens if Corlopam interacts with another drug?

The primary interaction documented in regulatory information is with beta-blockers, another class of blood pressure medicine. The official warning is that this combination could result in pronounced hypotension (low blood pressure) due to interference with the body's natural compensatory reflex.

Q: Are there special considerations for using Corlopam in children?

Yes, official guidelines outline special restrictions for pediatric use. The treatment duration is strictly limited to four hours in children (versus 48 hours in adults). Furthermore, official safety data notes that higher doses in children have been associated with worsened tachycardia, or fast heart rate.

Q: What happens if a dose of Corlopam is stopped suddenly?

Studies indicate that when the infusion was stopped, blood pressure gradually returned to pre-treatment levels. Regulatory data suggests that this process occurs without evidence of rebound hypertension (a sudden, severe increase in blood pressure).

Q: Does the body develop a tolerance to Corlopam with prolonged use?

Clinical studies, particularly those maintained for 48 hours, noted that some patients showed a suggestion of tolerance to the drug's effects at higher doses. However, a substantial effect on blood pressure was reported to persist.

Q: Why is Corlopam not available as a pill?

Corlopam is indicated for the rapid and quickly reversible management of severe hypertension. This therapeutic goal requires the immediate, controlled, and precise delivery of the medicine, which can only be achieved through continuous intravenous infusion.

Q: How do the effects of Corlopam end after treatment?

The drug is rapidly metabolized, or broken down, by the liver. Official regulatory information indicates that the drug’s components are then eliminated from the body primarily via the urine.

Storage and Disposal of Corlopam (Fenoldopam Mesylate)

The official labeling mandates specific storage conditions for Corlopam (fenoldopam mesylate) injection to maintain its integrity.

Storage Conditions

The undiluted vials must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). It is critical to protect the vials from light and ensure they are not frozen. Vials should be kept in their original container until use. After the drug is diluted, the solution must be discarded if not used within 4 hours at room temperature or 24 hours under refrigeration.

Handling and Disposal

Corlopam vials are for single use only. Any unused portion remaining in the container must be discarded. The disposal of unused or expired product must be carried out according to institutional procedures and all applicable local, state, and national requirements. As a general child safety precaution, the drug must be kept out of reach of children.